Farglitazar

In today's article, we will explore the fascinating world of Farglitazar. From its origins to its relevance in today's society, we will thoroughly examine all aspects related to this topic. We will analyze its impacts in different areas, such as economy, culture, science and technology, to understand its importance and influence on our daily lives. Throughout this article, we will learn about the various perspectives and opinions of experts on the subject, as well as testimonies from people who have participated in experiences related to Farglitazar. Get ready to embark on a journey of discovery and learning that will leave you with a broader and enriching vision about Farglitazar.

Farglitazar
Clinical data
Pregnancy
category
  • N/A
ATC code
  • none
Legal status
Legal status
  • Development discontinued
Identifiers
  • N-(o-Benzoylphenyl)-O--L-tyrosine
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC34H30N2O5
Molar mass546.623 g·mol−1
3D model (JSmol)
  • O=C(c1ccccc1)c2ccccc2N(C(=O)O)Cc5ccc(OCCc3nc(oc3C)c4ccccc4)cc5
  • InChI=1S/C34H30N2O5/c1-23-29(36-33(41-23)26-12-6-3-7-13-26)20-21-40-27-18-16-24(17-19-27)22-31(34(38)39)35-30-15-9-8-14-28(30)32(37)25-10-4-2-5-11-25/h2-19,31,35H,20-22H2,1H3,(H,38,39)/t31-/m0/s1 ☒N
  • Key:ZZCHHVUQYRMYLW-HKBQPEDESA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Farglitazar is a peroxisome proliferator-activated receptor agonist which was formerly under development by GlaxoSmithKline, but has never been marketed. It progressed to phase II clinical trials for the treatment of hepatic fibrosis, but failed to show efficacy.[1] After reaching phase III for type 2 diabetes, further development was discontinued.[2][3]

References

  1. ^ McHutchison J, Goodman Z, Patel K, Makhlouf H, Rodriguez-Torres M, Shiffman M, et al. (April 2010). "Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection". Gastroenterology. 138 (4): 1365–73, 1373.e1-2. doi:10.1053/j.gastro.2009.12.003. PMID 20004661.
  2. ^ "Farglitazar". Adis Insight. Springer Nature Switzerland AG.
  3. ^ "Farglitazar". pharmacodia.com.
Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.